Tzu Chi Medical Journal
Volume 22, Issue 2 , Pages 90-95, June 2010

Effect of Intravenous N-acetylcysteine on Plasma Total Homocysteine and Inflammatory Cytokines During High Flux Hemodialysis

  • Jen-Pi Tsai

      Affiliations

    • Department of Nephrology, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
    • ,
  • Fwu-Lin Yang

      Affiliations

    • Surgical Critical Care Unit, Buddhist Tzu Chi General Hospital, Taipei Branch, Taipei, Taiwan
    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Chih-Hsien Wang

      Affiliations

    • Department of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Te-Chao Fang

      Affiliations

    • Department of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Ru-Ping Lee

      Affiliations

    • Department of Nursing, Tzu Chi University, Hualien, Taiwan
    • ,
  • Bang-Gee Hsu

      Affiliations

    • Department of Nephrology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
    • School of Medicine, Tzu Chi University, Hualien, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Nephrology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan

Received 2 September 2009; received in revised form 22 September 2009; accepted 10 June 2010.

Article Outline

Abstract 

Objective

Hyperhomocysteinemia and increased inflammatory cytokines are independent risk factors in patients with renal diseases. N-acetylcysteine (NAC) is an antioxidant that is known to decrease inflammatory cytokines and plasma total homocysteine (tHcy). Therefore, the aim of this study was to compare normal saline injection with and without intravenous NAC during hemodialysis (HD) in terms of changes in serum levels of tumor necrosis factor-α (TNF-α, interleukin-10 (IL-10), high-sensitivity C-reactive protein (hs-CRP) and plasma tHcy.

Patients and Methods

In total, 43 high flux HD patients were enrolled at a 4-hour HD session and split into two groups, NAC (n = 22) and NS (n = 21) treatment groups, which received either a normal saline injection with intravenous NAC or without intravenous NAC, respectively. The NS group was divided into two subgroups, one with residual renal function (n = 5) and the other with anuria (n 16). The NAC group was also divided into two subgroups, one with residual renal function (n 6) and the other with anuria (n = 16). Serum TNF-α, IL-10, hs-CRP and tHcy were measured before and immediately after HD.

Results

There were no significant differences in baseline characteristics, TNF-α, IL-10, hs-CRP, and tHcy levels in intra- and intergroup comparisons. Compared to pre-HD baseline values, plasma tHcy level was lower after HD in the NS group (p<0.001), NS with anuria subgroup (p=0.001), NS with residual renal function subgroup (p = 0.034), NAC group (p < 0.001), NAC with residual renal function subgroup (p < 0.001), and NAC with anuria subgroup (p = 0.003). There were no statistically significant differences in plasma tHcy level when the NS group was compared with the NAC group. Plasma tHcy level was significantly lower in the NAC with residual renal function subgroup compared with the NS group (p = 0.002), the NAC with residual renal function subgroup compared with the NS with anuria subgroup (p<0.001), and the NAC with residual renal function subgroup compared with the NAC with anuria subgroup (p = 0.001). Moreover, the reduction in plasma tHcy level during HD was greater in the NAC with residual renal function subgroup than in the NAC with anuria subgroup (p = 0.001).

Conclusion

A normal saline injection is able to decrease plasma tHcy during high flux HD with or without NAC. However, a combination of the two further decreases plasma tHcy in high flux HD patients who still have residual renal function. NAC is only effective when there is residual renal function present to decrease plasma tHcy in high flux HD patients.

Keywords:  High flux hemodialysis , Homocysteine , N-acetylcysteine

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Harnett JD , Foley RN , Kent GM , Barre PE , Murray D , Parfrey PS . Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors . Kidney Int . 1995;47:884–890
  2. Stenvinkel P , Alvestrand P . Inflammation in end-stage renal disease: sources, consequences and therapy . Semin Dial . 2002;15:330–338
  3. Kennedy R , Case C , Fathi R , Johnson D , Isbel N , Marwick TH . Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? . Am J Med . 2001;110:198–204
  4. Kalantar-Zadeh K , Ikizler TA , Block G , Avram MM , Kopple JD . Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences . Am J Kidney Dis . 2003;42:864–881
  5. Arici M , Walls J . End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? . Kidney Int . 2001;59:407–414
  6. Stenvinkel P , Ketteler M , Johnson RJ , et al.   IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly . Kidney Int . 2005;67:1216–1233
  7. Rubin C , Nolin TD , Himmelfarb J . Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease? . Curr Opin Nephrol Hypertens . 2007;16:506–511
  8. Hsu BG , Yang FL , Lee RP , Peng TC , Harn HJ , Chen HI . N-acetylcysteine ameliorates lipopolysaccharide-induced organ damage in conscious rats . J Biomed Sci . 2004;11:152–162
  9. Hsu BG , Lee RP , Yang FL , Harn HJ , Chen HI . Post-treatment with N-acetylcysteine ameliorates the endotoxin shockinduced organ damage in conscious rats . Life Sci . 2006;79:2010–2016
  10. Ventura P , Panini R , Pasini MC , Scarpetta G , Salvioli G . N-acetylcysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion . Pharmacol Res . 1999;40:345–350
  11. Wang JH , Subeq YM , Tsai WC , Lee RP , Hsu BG . Intravenous N-acetylcysteine improves renal function and ameliorates plasma total homocysteine in patients undergoing cardiac angiography . Ren Fail . 2008;30:527–533
  12. Thaha M , Yogiantoro M , Tomino Y . Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease . Clin Drug Investig . 2006;26:195–202
  13. Scholze A , Rinder C , Beige J , Riezler R , Zidek W , Tepel M . Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure . Circulation . 2004;109:369–374
  14. Lee CC , Lee RP , Subeq YM , Wang CH , Fang TC , Hsu BG . Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients . Arch Med Res . 2008;39:785–790
  15. Himmelfarb J , Stenvinkel P , Ikizler TA , Hakim RM . The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia . Kidney Int . 2002;62:1524–1538
  16. Himmelfarb J , Hakim RM . Oxidative stress in uremia . Curr Opin Nephrol Hypertens . 2003;12:593–598
  17. Witko-Sarsat V , Gausson V , Nguyen AT , et al.   AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients . Kidney Int . 2003;64:82–91
  18. Perna AF , Acanfora F , Satta E , Lombardi C , Ingrosso D , De Santo NG . Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action . Semin Nephrol . 2004;24:426–430
  19. Mallamaci F , Zoccali C , Tripepi G , et al.   Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients . Kidney Int . 2002;61:609–614
  20. Ducloux D , Klein A , Kazory A , Devillard N , Chalopin JM . Impact of malnutrition-inflammation on the association between homocysteine and mortality . Kidney Int . 2006;69:331–335
  21. Jamison RL , Hartigan P , Kaufman JS , et al.   Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial . JAMA . 2007;298:1163–1170
  22. Perna AF , Luciano MG , Pulzella P , et al.   Is homocysteine toxic in uremia? . J Ren Nutr . 2008;18:12–17
  23. Friedman AN , Bostom AG , Laliberty P , Selhub J , Shemin D . The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study . Am J Kidney Dis . 2003;41:442–446
  24. Ventura P , Panini R , Abbati G , Marchetti G , Salvioli G . Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy . Pharmacology . 2003;68:105–114
  25. De Vriese AS , Langlois M , Bernard D , et al.   Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients . Nephrol Dial Transplant . 2003;18:2596–2600

PII: S1016-3190(10)60047-X

doi:10.1016/S1016-3190(10)60047-X

Tzu Chi Medical Journal
Volume 22, Issue 2 , Pages 90-95, June 2010

Article Tools